PATENT CLAIM ANALYSIS

Application Number: 16090415
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "571000"]

Abstract:
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.

Claim (Index 9):
Elafibranor for use according to  claim 1 , in combination to another anti-cholestatic agent.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.06061
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15496875', '16032380', '16030141', '15720849', '15903279']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.770466353145241
- 35 USC 102 Novelty (BERT): 0.5427466113020815
- Combined Prediction Score: 0.7476943789609252
- Mean Citation Score: 335.005982
- Max Citation Score: 368.9588
- Similarity Product: 189.3790974660397

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test